Facing the wrath of lawmakers on Capitol Hill Wednesday, a top Valeant Pharmaceutical official said he would recommend significant price reductions for two heart drugs that Valeant had previously marked up.
Investor Bill Ackman, an influential Valeant board member, told the Senate Aging Committee that he texted Valeant board chairman Robert Ingram during the hearing to suggest a conference call with the board this week to discuss cutting the prices of the drugs — isuprel and nitropress — by 30 percent.
Read Full Article »